Phathom Pharmaceuticals (PHAT)
(Delayed Data from NSDQ)
$12.21 USD
+0.39 (3.30%)
Updated Oct 3, 2025 04:00 PM ET
After-Market: $12.30 +0.09 (0.74%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PHAT 12.21 +0.39(3.30%)
Will PHAT be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for PHAT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PHAT
Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's Why
Wall Street Analysts See a 66.13% Upside in Phathom Pharmaceuticals (PHAT): Can the Stock Really Move This High?
PHAT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a Bet
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates
MannKind (MNKD) Reports Break-Even Earnings for Q2
Other News for PHAT
NR7 appears for PHAT after 3.3% move
Is PHAT signaling a buying opportunity? 20 Day Moving Average Support shows up after declining 3.82%
Is PHAT primed for upward momentum? Crossed Above 20 Day Moving Average shows up after advancing 4.42%
PHAT forms Pocket Pivot on September 30
12 Health Care Stocks Moving In Wednesday's After-Market Session